Interestingly, B2m–/– B16 tumor–bearing mice treated with r3LCMV showed improved tumor control relative to control-treated mice, suggesting that antigen presentation via MHC was not completely required for the antitumoral effect (Figure 3, A–C). The gene discussed is B2M; the disease is neoplasm.